Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ghost buyers
With only 6.3 mil shares outstanding,it will be very interesting how she trades once the regular trading market opens
Venus Concept Regains Compliance with Nasdaq’s Minimum Equity Requirement
TORONTO, June 06, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced that on June 4, 2024, it was notified by the Nasdaq Stock Market LLC (“Nasdaq”) that the Company had regained compliance with the stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) (“Minimum Equity Requirement”). Pursuant to Nasdaq Listing Rule 5815(d)(4)(B), the Company will be subject to a mandatory panel monitor through June 4, 2025.
The Nasdaq Staff originally issued the Company a deficiency notice on May 31, 2023, citing that stockholders’ equity as reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, was below the minimum $2,500,000 required for continued listing. On May 28, 2024, the Company completed a $35 million debt-to-equity transaction. As confirmed by the Nasdaq’s notice dated June 4, 2024, this transaction served to bring the Company into compliance with the Minimum Equity Requirement.
About Venus Concept
This stock sure gone crazy!
$1.70 pre mkt open
Thank you, bro.
Currently up 100%
Nice job!!! :)
Form-4 shows it was a sale = https://www.otcmarkets.com/filing/html?id=17130943&guid=FjQ-kWua4r7-B3h
She found some new sneakers
Jackpot! $6.20
Good morning! :) $2.40
That is because you are a serious investor/ trader, unlike so many others who cry that they can't wake up so early. Those are not "real" investors but 1st graders
Actelis Receives New Orders to Supply Three Military Bases with Cyber-Hardened Networking Technology, Continues Momentum with U.S. Military
Federal market expansion continues following key cybersecurity certifications
FREMONT, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ:ASNS) (“Actelis” or the “Company”), a market leader in cyber-hardened, rapid deployment networking solutions for IoT applications, today announced that it has received new orders for cyber-hardened networking technology to be deployed on three U.S. military bases. These orders were received following Actelis’ recent successful cybersecurity certifications and placement on the Department of Defense Information Network approved products list.
In January, Actelis announced that its solutions were placed on the Department of Defense Information Network (DoDIN) Approved Products List (APL) following certification from the Joint Interoperability Test Command (JITC). Then in February, the company announced that it achieved U.S. Department of Commerce National Institute of Standards and Technology (NIST) certification for FIPS 140-2 cryptographic standard. Both cybersecurity certifications are critical for the company to expand its portfolio of products within the military’s network ecosystem.
“We have invested significant resources on achieving these critical government security certifications,” said Tuvia Barlev, Chairman and CEO of Actelis. “We are very pleased to see that those efforts are resulting in new orders and a strong pipeline for our federal market segment.”
Actelis continues its momentum in the federal IoT space where it helps the U.S. military greatly accelerate its base modernization initiatives. The company’s unique hybrid-fiber networking solution enables the military to deliver immediate fiber-grade connectivity to critical IoT devices and systems without the need for heavy engineering or construction, saving months of project time and can save millions for military bases and federal campuses.
The Actelis solution, as the company believes, is the only one of its kind on the DoDIN APL, giving the company a strong competitive advantage. The company’s solution features a high level of data protection including 256-bit MACsec encryption, data fragmentation and scrambling, all of which strengthen the security of the network, particularly at the edge where IoT devices are very vulnerable to attacks.
KUDOS to you! Great job man. :)
Now that is the kind of spirit we need on these threads! GREAT FREEGIN CALL!!!!!!!!
MicroAlgo Inc. (NASDAQ: MLGO) Announced to Jointly Establish a Micro-Consciousness Quantum Research Center With WIMI (NASDAQ: WIMI)
BEIJING, June 4, 2024 /PRNewswire/ -- MicroAlgo Inc. (NASDAQ: MLGO) (the "Company" or "MicroAlgo"), today announced that MicroAlgo and WiMi will jointly establish a micro-consciousness quantum research center. It will integrate physics, mathematics, medicine, genetics, computer science, biology, polymer chemistry, philosophy, psychology, sociology, and many other disciplines to form a comprehensive research institute based on various disciplines centered on consciousness.
Research in basic science is a long process that requires a long-term commitment from scientists. At the same time, it also requires the support and promotion from the society and enterprises. Against the backdrop, MicroAlgo (NASDAQ: MLGO) and WiMi (NASDAQ: WIMI) plan to establish a micro-consciousness quantum research center together, aiming to utilize the characteristics of quantum theory, combined with the most cutting-edge artificial intelligence technology, to study the relationship between consciousness and quantum. Continuously explore the deep science, to unify the quantum and human consciousness, and expand the limitations of science.
The micro-consciousness quantum research center builds a bridge between basic science and applied technology, closely connecting the theoretical research of basic science and the practice of applied technology. It not only focuses on basic science research, but also promotes a arrange of innovative technologies in practice, and actively facilitates the transfer from research results to practical applications. From the vision of globalization, the center will integrate the world's top resources and gather talents from the world, and is committed to becoming an international innovation platform for quantum information science, artificial intelligence, neuroscience and biology, and to lead towards a future where artificial intelligence and quantum science will go hand in hand. The core research directions of the micro-consciousness quantum research center are as follows.
1. Quantum computing and consciousness model: Utilizing the principles and advantages of quantum computing to research the nature of the conscious phenomenon. Build a quantum algorithm to simulate the dynamic behavior of neuronal networks and the brain's activities in cognition, perception, and decision-making. The goal is to develop quantum models of consciousness capable of performing highly complex tasks, which may include, but are not limited to, emotion recognition, creative thinking simulations, and quantitative analysis of states of consciousness.
2. Brain-computer interface technology: Exploring the theoretical framework and practice for the integration of consciousness and machine, researching and developing the next-generation intelligent interface. Develop high-precision quantum sensors for monitoring brain activities. At the same time, utilizing quantum encryption technology to ensure the security of data transmission during brain-computer interaction. In addition, explores the use of quantum computing processing capabilities to decode brain signals in real-time to achieve more efficient human-machine interaction, laying a solid foundation for future human-machine applications.
3. Big data AI and quantum consciousness: Simulating the working mechanism of the human brain, combining quantum computing with artificial intelligence to build a new generation of intelligent systems, creating a quantum-enhanced AI system, and unlocking the mysteries of consciousness and the quantum world. Promote the application of quantum computing in simulating brain functions and optimizing machine learning algorithms, and explore the use of quantum features to enhance the cognitive ability and creativity of AI, in a bid to develop a humanoid AI system based on quantum consciousness to open a new era of intelligence.
4. Quantum-driven generative consciousness: Explore the potential connection between the conscious phenomenon and the principles of quantum physics, understand the nature of consciousness at the quantum level, construct a cross-disciplinary technical theoretical system, and provide theoretical support for the development of consciousness science.
Micro-consciousness quantum research center establishes a deep alliance with top universities and research institutes in China based on mutual trust, and the modes of cooperation include joint research and development, building joint laboratories, building industrial institutes, building engineering experiment centers, and training talents together. Specifically, through the joint R&D project, scientific research resources can be shared, and the resource advantages of both sides can be pooled together to overcome the major scientific problems in the field of consciousness quantum science. Through the construction of joint laboratories and industrial institutes, theoretical research and practical teaching can be closely integrated to provide researchers with learning and research opportunities close to the frontiers of the industry. At the same time, accelerates the transfer from scientific research results to industrial applications. The joint construction of the engineering experiment center provides a platform for the development and testing of new technologies and accelerates the development of technology. The micro-consciousness quantum research center will bridge the gap between theoretical research and practical applications, and promote human society to step into a new era that is smarter, more virtual and more efficient.
About MicroAlgo Inc.
MicroAlgo Inc. (NASDAQ: MLGO) Announced to Jointly Establish a Micro-Consciousness Quantum Research Center With WIMI (NASDAQ: WIMI)
BEIJING, June 4, 2024 /PRNewswire/ -- MicroAlgo Inc. (NASDAQ: MLGO) (the "Company" or "MicroAlgo"), today announced that MicroAlgo and WiMi will jointly establish a micro-consciousness quantum research center. It will integrate physics, mathematics, medicine, genetics, computer science, biology, polymer chemistry, philosophy, psychology, sociology, and many other disciplines to form a comprehensive research institute based on various disciplines centered on consciousness.
Research in basic science is a long process that requires a long-term commitment from scientists. At the same time, it also requires the support and promotion from the society and enterprises. Against the backdrop, MicroAlgo (NASDAQ: MLGO) and WiMi (NASDAQ: WIMI) plan to establish a micro-consciousness quantum research center together, aiming to utilize the characteristics of quantum theory, combined with the most cutting-edge artificial intelligence technology, to study the relationship between consciousness and quantum. Continuously explore the deep science, to unify the quantum and human consciousness, and expand the limitations of science.
The micro-consciousness quantum research center builds a bridge between basic science and applied technology, closely connecting the theoretical research of basic science and the practice of applied technology. It not only focuses on basic science research, but also promotes a arrange of innovative technologies in practice, and actively facilitates the transfer from research results to practical applications. From the vision of globalization, the center will integrate the world's top resources and gather talents from the world, and is committed to becoming an international innovation platform for quantum information science, artificial intelligence, neuroscience and biology, and to lead towards a future where artificial intelligence and quantum science will go hand in hand. The core research directions of the micro-consciousness quantum research center are as follows.
1. Quantum computing and consciousness model: Utilizing the principles and advantages of quantum computing to research the nature of the conscious phenomenon. Build a quantum algorithm to simulate the dynamic behavior of neuronal networks and the brain's activities in cognition, perception, and decision-making. The goal is to develop quantum models of consciousness capable of performing highly complex tasks, which may include, but are not limited to, emotion recognition, creative thinking simulations, and quantitative analysis of states of consciousness.
2. Brain-computer interface technology: Exploring the theoretical framework and practice for the integration of consciousness and machine, researching and developing the next-generation intelligent interface. Develop high-precision quantum sensors for monitoring brain activities. At the same time, utilizing quantum encryption technology to ensure the security of data transmission during brain-computer interaction. In addition, explores the use of quantum computing processing capabilities to decode brain signals in real-time to achieve more efficient human-machine interaction, laying a solid foundation for future human-machine applications.
3. Big data AI and quantum consciousness: Simulating the working mechanism of the human brain, combining quantum computing with artificial intelligence to build a new generation of intelligent systems, creating a quantum-enhanced AI system, and unlocking the mysteries of consciousness and the quantum world. Promote the application of quantum computing in simulating brain functions and optimizing machine learning algorithms, and explore the use of quantum features to enhance the cognitive ability and creativity of AI, in a bid to develop a humanoid AI system based on quantum consciousness to open a new era of intelligence.
4. Quantum-driven generative consciousness: Explore the potential connection between the conscious phenomenon and the principles of quantum physics, understand the nature of consciousness at the quantum level, construct a cross-disciplinary technical theoretical system, and provide theoretical support for the development of consciousness science.
Micro-consciousness quantum research center establishes a deep alliance with top universities and research institutes in China based on mutual trust, and the modes of cooperation include joint research and development, building joint laboratories, building industrial institutes, building engineering experiment centers, and training talents together. Specifically, through the joint R&D project, scientific research resources can be shared, and the resource advantages of both sides can be pooled together to overcome the major scientific problems in the field of consciousness quantum science. Through the construction of joint laboratories and industrial institutes, theoretical research and practical teaching can be closely integrated to provide researchers with learning and research opportunities close to the frontiers of the industry. At the same time, accelerates the transfer from scientific research results to industrial applications. The joint construction of the engineering experiment center provides a platform for the development and testing of new technologies and accelerates the development of technology. The micro-consciousness quantum research center will bridge the gap between theoretical research and practical applications, and promote human society to step into a new era that is smarter, more virtual and more efficient.
About MicroAlgo Inc.
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Successfully Delivered First Development Candidate to Biogen; $8 Million Payment Earned
Established a Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Focused on Two Critical Oncogenic Proteins
Progressed Phase 1 Dose Escalation Trials for Cemsidomide (CFT7455) and CFT1946; Data from Both Trials Expected in 2H 2024
Cash, Cash Equivalents and Marketable Securities Total $299.2 Million as of March 31, 2024; Expected to Provide Runway into 2027
WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the first quarter ended March 31, 2024, as well as recent business highlights.
“We are off to a strong start in 2024 with enrollment progressing well in our ongoing Phase 1/2 trials of CFT7455, now known as cemsidomide, and CFT1946. We look forward to maintaining this momentum and are on track for clinical readouts from both trials in the second half of the year,” said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. “During the first quarter, we continued to leverage our discovery expertise as we entered into a new license and collaboration agreement with Merck KGaA, Darmstadt, Germany and delivered our first development candidate to Biogen. Together, these accomplishments further validate the excitement around our TORPEDO® platform and our ability to design innovative molecules for a range of diseases where degraders have the potential to become new therapeutic options for patients searching for treatments.”
FIRST QUARTER 2024 AND RECENT ACHIEVEMENTS
Cemsidomide (CFT7455): Cemsidomide (CFT7455) is an oral degrader of IKZF1/3 for the potential treatment of relapsed/refractory (R/R) multiple myeloma (MM) and R/R non-Hodgkin’s lymphomas (NHL).
Advanced the Phase 1/2 Clinical Trial. The dose escalation portion of the Phase 1/2 trial evaluating cemsidomide (CFT7455) in combination with dexamethasone for R/R MM and as a monotherapy for R/R NHL continues to enroll patients. For the combination with dexamethasone MM arm, the 62.5 µg dose has been declared safe and patients are enrolling at a higher dose level. Simultaneously, additional patients are enrolling in the 62.5 µg expansion cohort. For the monotherapy NHL arm, the 62.5 µg cohort has been declared safe and patients are enrolling at a higher dose level.
CFT1946: CFT1946 is an oral degrader targeting BRAF V600X mutations for the potential treatment of solid tumors including non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and melanoma.
Advanced the Phase 1/2 Clinical Trial. The dose escalation portion of the CFT1946 Phase 1/2 trial for BRAF V600X mutations, including NSCLC, CRC and melanoma, continues to enroll patients. The 320 mg dose has been declared safe and patients are enrolling at a higher dose level. Simultaneously, additional patients are enrolling at the 160 mg and 320 mg dose levels for pharmacokinetic, pharmacodynamic and anti-tumor activity evaluation.
Presented New Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024. In April 2024, C4T presented preclinical data highlighting superior activity of CFT1946 compared to BRAF inhibitor standard of care combinations in models of BRAF V600X NSCLC, CRC, melanoma and brain metastasis.
Trial-in-Progress Poster Accepted at European Society for Medical Oncology Congress (ESMO) Gastrointestinal (GI) Cancers Congress 2024. C4T will present a trial-in-progress poster on the CRC opportunity within the ongoing CFT1946 Phase 1/2 trial at ESMO GI 2024, taking place from June 26 to June 29, 2024.
Collaborations:
Delivered development candidate to Biogen. In April 2024, C4T earned an $8 million payment after Biogen accepted delivery of a development candidate in an undisclosed indication. Biogen is responsible for all future clinical development and commercialization for this program.
License and collaboration agreement with Merck KGaA, Darmstadt, Germany (MKDG). In March 2024, C4T entered into a license and collaboration agreement with MKDG to exclusively discover two targeted protein degraders against critical oncogenic proteins that C4T has progressed within its internal discovery pipeline. Under the terms of the agreement, C4T received an upfront payment of $16 million. MKDG will fund C4T’s discovery research efforts. C4T has the potential to receive up to approximately $740 million in discovery, regulatory and commercial milestone payments across the collaboration. In addition, C4T is eligible for mid-single to low-double digit tiered royalties on future sales for each program.
CORPORATE UPDATES
In April 2024, Dan Powers, DO, was appointed as senior vice president, clinical development. Dr. Powers brings over 20 years of leadership experience in clinical development and medical affairs within the hematology and solid tumor space. Dr. Powers reports to C4T’s chief medical officer, Len Reyno, M.D., and is responsible for leading clinical development programs as well as supporting and executing our ongoing clinical studies.
KEY UPCOMING MILESTONES
Cemsidomide (CFT7455):
Present updated data from the ongoing Phase 1 dose escalation trial in R/R MM in 2H 2024.
Present data from the ongoing Phase 1 dose escalation trial in R/R NHL in 2H 2024.
Complete Phase 1 dose exploration in R/R MM and R/R NHL by year-end 2024.
CFT1946:
Present data from the ongoing Phase 1 monotherapy dose escalation trial in NSCLC, CRC, melanoma and other cancers with BRAF V600X mutations in 2H 2024.
FIRST QUARTER 2024 FINANCIAL RESULTS
Revenue: Total revenue for the first quarter of 2024 was $3.0 million, compared to $3.8 million for the first quarter of 2023. The decrease in revenue was primarily due to the Biogen and Calico research terms ending in 2023. In 2024, we commenced work on our new collaboration agreements with Merck Sharp & Dohme LLC (Merck) and MKDG, which were signed in December 2023 and March 2024, respectively. Total revenue for the first quarter of 2024 reflects revenue recognized under our collaborations with MKDG, Merck, Roche and Biogen, and total revenue recognized in the first quarter of 2023 reflects revenue recognized under collaboration agreements with Roche, Biogen and Calico.
Research and Development (R&D) Expense: R&D expense, net of a one-time $1.9 million restructuring charge, was $22.5 million for the first quarter of 2024. This is compared to $29.0 million for the first quarter of 2023. The reduction in R&D expense was primarily due to the prioritization of our internal discovery efforts and stopping clinical development for CFT8634, partially offset by increased clinical trial expense as cemsidomide (CFT7455) and CFT1946 continue to advance.
General and Administrative (G&A) Expense: G&A expense, net of a one-time $0.5 million restructuring charge, was $10.3 million for the first quarter of 2024. This is compared to $10.9 million for the first quarter of 2023. The decrease in G&A expense was primarily attributable to a reduction in external consulting spend.
Net Loss and Net Loss per Share: Net loss for the first quarter of 2024 was $28.4 million, compared to $34.8 million for the first quarter of 2023. Net loss per share for the first quarter of 2024 was $0.41 compared to $0.71 for the first quarter of 2023.
Cash Position and Financial Guidance: Cash, cash equivalents and marketable securities as of March 31, 2024 were $299.2 million, compared to $281.7 million as of December 31, 2023. The increase was primarily the result of proceeds received in January 2024 from the sale of shares of our common stock to a subsidiary of our partner Betta Pharmaceuticals and proceeds from settlement of shares under our at the market (ATM) offering arrangement, both of which were previously disclosed. These inflows were partially offset by cash used in operating activities. C4T expects that its cash, cash equivalents and marketable securities as of March 31, 2024 will be sufficient to fund planned operating expenses and capital expenditures into 2027.
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.
About cemsidomide (CFT7455)
Cemsidomide (CFT7455) is an orally bioavailable MonoDAC™ degrader designed to be highly potent and selective against its intended targets of Ikaros (IKZF1) and Aiolos (IKZF3) and overcome shortcomings of currently approved therapies to treat multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL). Cemsidomide (CFT7455) is currently in a Phase 1 dose escalation study in MM and NHL. Initial clinical data show cemsidomide (CFT7455) is well tolerated, demonstrates anti-myeloma activity and displays evidence of immunomodulatory effects. More information about this trial may be accessed at www.clinicaltrials.gov (identifier: NCT04756726).
About CFT1946
CFT1946 is an orally bioavailable BiDAC™ degrader designed to be potent and selective against BRAF V600X mutant targets. In preclinical studies, CFT1946 is active in vivo and in vitro in models with BRAF V600E driven disease and in models resistant to BRAF inhibitors. CFT1946 is currently in a Phase 1 dose escalation study in BRAF V600X mutant solid tumors including
Gaucho Group (VINO) Supports Strong Investment in Argentina Following Endorsements from Global Leaders
https://www.streetinsider.com/Corporate+News/Gaucho+Group+%28VINO%29+Supports+Strong+Investment+in+Argentina+Following+Endorsements+from+Global+Leaders/23184545.html
Shareholder vote results are gonna be out on June 20th
https://www.otcmarkets.com/filing/html?id=17484687&guid=HdQ-knnQ9HXCJth
MARPAI INC. ANNOUNCES COST REDUCTION PROGRAM AND PROPERTY SUBLEASE
TAMPA, Fla., May 2, 2024 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (Nasdaq: MRAI), an independent national Third-Party Administration (TPA) company transforming the $22 billion TPA market supporting self-funded employer health plans with affordable, intelligent, healthcare, today announced the implementation of a comprehensive cost reduction program and the sublease of one of its properties. These initiatives are expected to generate $3 million in annual savings and position the Company for continued financial strength.
The cost reduction program, meticulously developed by Marpai's leadership team, identifies and implements strategic measures to streamline operations and optimize expenditures. This program is anticipated to yield approximately $3 million in annual savings across various areas of the business.
"We are committed to operational excellence and maximizing shareholder value," said Damien Lamendola, CEO of Marpai Inc. "This cost reduction program demonstrates our proactive approach to financial stewardship. By implementing these measures, we expect to enhance our path to profitability while maintaining the high level of service our clients and members expect."
In addition to the cost reduction program, Marpai has successfully subleased one of its properties. This strategic move frees up capital and reduces ongoing operational costs associated with the property.
"The sublease agreement allows us to optimize our real estate portfolio and generate additional savings," said John Powers, Marpai's President. "We are confident that this decision will contribute positively to our long-term financial performance."
We recently welcomed a new addition to our Coralville, IA laboratory: A fully automated programmable catalyst coating system from Sono-Tek. Designed for mid-volume production, this state of the art catalyst coating unit will play a key role in accelerating our goal of producing 1m² green hydrogen panels.
Our team appreciated the chance to spend the day with a Sono-Tek representative and get acquainted with the capabilities of the new system.
Thank you, Sono-Tek Corp. Ultrasonic Coating Systems!
It will be a blockbuster! Have a beautiful weekend
Why? The number of outstanding shares of each of the issuer’s classes of capital or common stock as of December 31, 2023 was: 1,189,577,722 Ordinary Shares
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
April 26, 2024
Biodexa Pharmaceuticals PLC
(“Biodexa” or the “Company”)
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the
Treatment of Familial Adenomatous Polyposis (FAP)
Worldwide rights come with $17 million in non-dilutive grant funding for Pivotal Phase 3 trial in FAP
An estimated 100,000 in U.S. and Europe are afflicted with FAP, precancerous polyps that typically lead to surgical removal of the colon and/or rectum
In FAP, eRapa holds the potential of delaying or preventing surgical intervention
Multiple opportunities seen in other indications, including bladder and prostate cancers
FAP is a substantially genetic orphan disease for which there are no approved therapeutic options; the current standard of care is surveillance and surgery
Phase 3 FAP program is supported by a $17 million grant awarded from the Cancer Prevention and Research Institute of Texas (“CPRIT”) in a competitive process
Phase 2 results in FAP to be presented at two leading scientific conferences in Q2 ‘24
Ongoing Phase 2 study in Non-muscle Invasive Bladder Cancer expected to read-out in Q2 ‘25
Phase 2 study in NMI Bladder Cancer supported by $3 million grant from National Cancer Institute, part of the National Institutes of Health
Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced it entered into a definitive agreement with Rapamycin Holdings Inc. (d/b/a Emtora Biosciences) (“Emtora”) for the rights to eRapa under an exclusive, worldwide license (with the ability to grant sublicenses) to develop, manufacture, commercialize and otherwise advance the clinical potential of eRapa.
Stephen Stamp, CEO and CFO of Biodexa said, “Acquiring a Phase 3 ready asset, particularly one supported by $17 million of non-dilutive grant funding, significantly advances Biodexa’s oncology pipeline and adds numerous valuation catalysts for our stakeholders. We are delighted to be working with the Emtora team which has excelled in bringing eRapa close to the end of Phase 2 in Non-muscle Invasive Bladder Cancer and to the beginning of a Phase 3 trial in FAP, a devastating disease for which there is currently no approved pharmacological agent for altering its progression. Left untreated, it almost always leads to incredibly invasive surgery and a major deterioration in the quality of life.”
Stephen Dufilho, Executive Chairman of Emtora added, “The transaction with Biodexa is the culmination of a decade-long effort to advance our potentially game-changing eRapa to a registrational Phase 3 trial - and ultimately to patients in need. Our story began in San Antonio – where eRapa was originally invented at the University of Texas and funded in part by grants from the Cancer Prevention Research Institute of Texas. We thank the scientists, clinicians, investors and biotech executives that supported our efforts to reach this important milestone. We look forward to working with the Biodexa team as we embark upon this next chapter.”
About eRapa
eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorgenesis1. Rapamycin is approved in the US for organ rejection in renal transplantation as Rapamune®(Pfizer). Through the use of nanotechnology and pH sensitive polymers, eRapa is designed to address the poor bioavailability, variable pharmacokinetics and toxicity generally associated with the currently available forms of rapamycin. eRapa is protected by a number of issued patents which extend through 2035, with other pending applications potentially providing further protection beyond 2035.
eRapa in FAP
FAP is characterized as a proliferation of polyps in the colon and/or rectum, usually occurring in mid-teens. There is no approved therapeutic option for treating FAP patients, for whom active surveillance and surgical resection of the colon and/or rectum remain the standard of care. If untreated, FAP typically leads to cancer of the colon and/or rectum. There is a significant hereditary component to FAP with a reported incidence of one in 5,000 to 10,000 in the US2 and one in 11,300 to 37,600 in Europe3. eRapa has received Orphan Designation in the US with plans to seek such designation in Europe. Importantly, mTOR has been shown to be over-expressed in FAP polyps – thereby underscoring the rationale for using a potent and safe mTOR inhibitor like eRapa to treat FAP.
Emtora is currently completing an open-label, multi-center Phase 2 study in 30 patients with confirmed FAP with the primary endpoints of safety and tolerability, and percentage change in polyp burden after six months of treatment with eRapa. The Phase 2 study was partially funded by a $3.0 million grant from CPRIT.
Won't remain quiet much longer. My bid is in.🥰
Currently, $6.53 shorts playing with fire! They will BURN!🥵
Beautiful News this morning = Amesite Launches Revolutionary NurseMagic™ App in Beta to Empower 5.2 Million Nurses with AI Tools
New App Marks Amesite’s Entry into B2C AI Mobile Applications Market
DETROIT, April 24, 2024 (GLOBE NEWSWIRE) -- Amesite Inc. (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform for business and education markets, today announced the beta release of NurseMagic™, an innovative and proprietary app designed for nurses. This new web app uses AI to provide helpful and easy-to-use tools for over 5.2 million nurses, making their daily tasks easier and more efficient. Additionally, with its status as a Joint Provider with PACE, also offers convenient, accredited continuing education (CE) programs to nurses on the app, enabling them to meet requirements for licensure.
NurseMagic™ features include:
MedDecode: Quickly translates medical terms into simple language.
Professional Email Generator: Creates practical work emails quickly.
CareTalk: Assists nurses in talking to patients effectively and with compassion.
Wellness Break: Coaches nurses on taking effective breaks during the day.
MedExplainer: Enables nurses to explain medical practices to patients.
Image-to-Text: Converts images to text for easy reading and communication.
MedUverse: Offers key information about medications.
NurseTea: Collects instant feedback through surveys that are shared with the community.
To request an invitation to participate in the NurseMagic™ Beta, nurses can visit this site: https://www.nursemagic.ai/
Sai Nittala, Senior AI Manager at Amesite, emphasizes the collaborative role of AI in healthcare: “AI is a partner in the nursing field, enhancing the valuable human elements of nursing care with powerful technology. NurseMagic™ is developed with the vision that AI supports nurses, allowing them to focus more on patient care and less on routine tasks, thereby enriching their professional practice on a daily basis.”
Dr. Ann Marie Sastry, CEO of Amesite, said, “Launching apps enables us to directly reach much larger audiences. We want to equip every nurse on the planet with tools that deliver immediate, qualified information, and address the demands on their time while leveraging their expertise. We intend to partner in this sector as we provide professional learning right on the app, and plan to have more announcements as we roll out additional features.”
Short sellers love this stock and now starting to cover. It's a perfect time to buy back in IMO. Next target $18
Nice Earnings report = WANG & LEE GROUP, INC. Announces Fiscal Year 2023 Financial Results
HONG KONG, China, April 18, 2024 (GLOBE NEWSWIRE) -- WANG & LEE GROUP, Inc. (Nasdaq: WLGS) (“WLGS” or the “Company”), is a British Virgin Islands holding company with operations conducted by its subsidiaries in Hong Kong. The Company is a construction prime and subcontractor engaging in the installation of Electrical & Mechanical Systems (“E&M”), which include low voltage (220v/phase 1 or 380v/phase 3) electrical systems, mechanical ventilation and air-conditioning (“MVAC”) systems, fire service systems, water supply and sewage disposal system installation and fitting out for the public and private sectors. The Company today announced its unaudited operating results for the year ended December 31, 2023.
Financial Highlights for the Fiscal Year 2023:
? Revenue increased by 63.7% to $6.83 million for the fiscal year 2023 ended December 31, 2023, from $4.17 million for the fiscal year ended December 31, 2022
? Gross profit increased by 210.6% to $2.44 million for the fiscal year 2023 ended December 31, 2023, from $0.79 million for the fiscal year ended December 31, 2022, respectively.
? Total shareholders’ equity increased by 449.0% to $5.98 million for the fiscal year ended December 31, 2023, from deficit of $1.71 million for the year ended December 31, 2022
Mr. Pui Lung Ho, Chief Executive Officer of the Company, commented: “During the fiscal year 2023, we continue to enhance the diversity of our product and service line by introducing new products and services, expanding into target markets, and offering products with different features and offering products with different features and functionalities to meet a broader range of customer needs, which is demonstrated by the Company’s sales growth of over 63% in the fiscal year 2023.”
Below is the summary presenting the Company’s revenues disaggregated by products and services:
Fiscal Year 2023 Financial Results Overview
Other Key Performance Indicators
Adjusted EBITDA and Adjusted EBITDA Margin
Adjusted EBITDA represents net income before interest expense, net, provision (benefit) for income taxes, and depreciation. Adjusted EBITDA Margin represents Adjusted EBITDA as a percentage of revenues for each period. These metrics are supplemental measures of our operating performance that are neither required by, nor presented in accordance with, GAAP. These measures should not be considered as an alternative to net income, or any other performance measure derived in accordance with GAAP as an indicator of our operating performance. We present Adjusted EBITDA and Adjusted EBITDA Margin as management uses these measures as key performance indicators, and we believe they are measures frequently used by securities analysts, investors and other parties to evaluate companies in our industry. These measures have limitations as analytical tools and should not be considered in isolation or as substitutes for analysis of our results as reported under GAAP.
Our calculation of Adjusted EBITDA and Adjusted EBITDA Margin may not be comparable to similarly named measures reported by other companies. Potential differences between our measure of Adjusted EBITDA compared to other similar companies’ measures of Adjusted EBITDA may include differences in capital structures, tax positions and the age and book depreciation of tangible assets.
The following table presents a reconciliation of net income, the most directly comparable measure calculated in accordance with GAAP, to Adjusted EBITDA, and the calculation of Adjusted EBITDA Margin for each of the periods presented.
Reconciliation To GAAP Information:
2023 2H 2023 1H For the years ended December 31,
(Q3 & Q4) (Q1 & Q2) 2023 2022
Consolidated Net Income (Loss) (GAAP) $ 1,295,994 $ (1,624,099 ) $ (328,105 ) $ (596,881 )
Interest expenses 36,967 24,597 61,564 35,377
Income taxes - - - -
Depreciation 31,799 614 32,413 2,603
Adjusted EBITDA (Non-GAAP) $ 1,364,760 $ (1,598,888 ) $ (234,128 ) $ (558,901 )
Adjusted EBITDA Margin 25.32 % (111.29 )% (3.43 )% (13.40 )%
Results of Operations
For the second half and the first half for the fiscal Year 2023, the years ended December 31, 2023 and 2022,
The following table sets forth a summary of our consolidated results of operations for the second half and the first half for the fiscal Year 2023, the years ended December 31, 2023 and 2022. The historical results presented below are not necessarily indicative of the results that may be expected for any future period.
For the years ended
December 31,
2023 2H
(Q3 & Q4) 2023 1H
(Q1 & Q2) 2023 2022
Contract revenue $ 5,389,143 $ 1,436,736 $ 6,825,879 $ 4,169,931
Contract costs (3,201,025 ) (1,184,254 ) (4,385,279 ) (3,384,227 )
GROSS PROFIT $ 2,188,118 $ 252,482 $ 2,440,600 $ 785,704
Less: General and administrative expenses (997,080 ) (1,893,861 ) (2,890,941 ) (1,427,156 )
Add: Other income 104,956 17,280 122,236 44,571
Less: Provision for Income Taxes - - - -
NET PROFIT / (LOSS) $ 1,295,994 $ (1,624,099 ) $ (328,105 ) $ (596,881 )
Foreign Currency Translation Adjustment 24,971 (3,459 ) 21,512 (130 )
TOTAL COMPREHENSIVE INCOME / (LOSS) $ 1,320,965 $ (1,627,558 ) $ (306,593 ) $ (597,011 )
Revenue
Our sales were $5.39 million for the second half of the fiscal year 2023, which increased by $3.95 million, or 275.1% from $1.44 million for the first half of the fiscal year 2023.
Our sales were $6.83 million for the fiscal year 2023 ended December 31, 2023, which increased by $2.66 million, or 63.7% from $4.17 million for the same period of 2022. During the fiscal year 2023, one of our largest construction projects was suspended since the first quarter of 2023 until July 2023 due to work delays caused by a third party to our client. Since the revenue is recognized based on the stages of site work, we posted a relatively low revenue in the first half year of the fiscal year 2023 comparing to the second half year of the fiscal year 2023. We successfully charged the client for the loss and damage caused by the suspension while resume the site work.
Cost of revenues
Our cost of revenues were $3.20 million for the second half of the fiscal year 2023, which increased by $2.02 million, or 170.3% from $1.18 million for the first half of the fiscal year 2023.
Our cost of revenues were $4.39 million for the fiscal year 2023 ended December 31, 2023, which increased by $1.01 million, or 29.6% from $3.38 million for the same period of 2022. The increase of the cost of revenues is due to the growth of revenues in the second half year of the fiscal year 2023 and a termination of a sub-contractor due to delayed progress which created higher cost of new engagements for the replacement and caught up the delays in the first half year of the fiscal year 2023.
Gross profit
Our gross profit was $2.19 million for the second half of the fiscal year 2023, which increased by $1.94 million, or 766.6% from $0.25 million for the first half of the fiscal year 2023.
Our gross profit was $2.44 million for the fiscal year 2023 ended December 31, 2023, which increased by $1.65 million, or 210.6% from $0.79 million for the same period of 2022. The significant increase of gross profit margin was caused by the demand of charge to client for the unilaterally suspension.
General and administrative expenses
General and administrative expenses amounted to approximately $1.00 million for the second half of the fiscal year 2023, which decreased by $0.89 million, or 47.4% from $1.89 million for the first half of the fiscal year 2023.
General and administrative expenses amounted to approximately $2.89 million for the fiscal year 2023 ended December 31, 2023, which increased by $1.46 million or 102.6% from $1.43 million for the same period of 2022. This increase was mainly due to the increase of cost after listing, the related cost such as listing fee, legal and professional fees, and salary payment.
General and administrative expenses include rental expenses, staff salary and benefits, legal and professional fees, office expenses, travel expenses, entertainment, depreciation and listing fees.
Interest Expenses
Interest expenses amounted to $36,967 for the second half of the fiscal year 2023, which increased by $12,370, or 50.3% from $24,597 for the first half of the fiscal year 2023.
Interest expenses amounted to $61,564 for the fiscal year 2023 ended December 31, 2023, which increased by $26,187, or 74.0% from $35,377 for the same period of 2022. During the fiscal year of 2023, we engaged into an additional bank facility to allow the group to increase the utilization of debt equity ratio, while also allowed us to offset the interest rate risk by in-house interest rate hedged.
Other Income
Other income amounted to $141,923 for the second half of the fiscal year 2023, which increased by $100,046, or 238.9% from $41,877 for the first half of the fiscal year 2023.
Other income amounted to $183,800 for the fiscal year 2023 ended December 31, 2023, which increased by $103,852, or 129.9% from $79,948 for the same period of 2022.
Net loss
Net profit was $1.30 million for the second half of the fiscal year 2023, which increased by $2.92 million, or 179.8% from net loss of $1.62 million for the first half of the fiscal year 2023.
Net loss was $0.33 million for the fiscal year 2023 ended December 31, 2023, which increased by $0.27 million, or 45.0% as compared to $0.60 million for the same period of 2022.
Equity
Our Shareholders’ Equity increased by 28.4% and 449.0% to $5.98 million for the fiscal year 2023 ended December 31, 2023, from $4.66 million for six months ended June 30, 2023 and deficit of $1.71 million for the year ended December 31, 2022 respectively.
About WANG & LEE GROUP, Inc.
MARPAI INC. ANNOUNCES SALE OF $11.83 MILLION CONVERTIBLE NOTES
Financing Strengthens Marpai's Growth Trajectory
TAMPA, Fla., April 16, 2024 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (Nasdaq: MRAI), an independent national Third-Party Administration company transforming the $22 billion TPA market supporting self-funded employer health plans with affordable, intelligent, healthcare, today announced the sale of new three-year, $11.83 million convertible notes to funds managed by JGB Management Inc.
The loan proceeds will be used to repay Marpai's existing debt with Libertas Funding, fuel Marpai's ongoing growth initiatives and bolster working capital.
Key Highlights of the Loan Agreement:
Total Loan Amount: $11.83 million
Term: Three years
Use of Proceeds: Debt repayment, growth initiatives and working capital
Convertible Note Provision: The notes are convertible into Marpai common stock at a price of $3.00 per share. This represents a premium to the current market price of Marpai's common stock. The convertible note also provides for price protection in the event Marpai issues shares below the applicable conversion price subject to the floor of $2.23 per share.
"The proceeds from the sale of the convertible notes provides us with the financial flexibility to accelerate our growth strategy and further solidify our position as a leader in the self-funded employer health plan market," said Damien Lamendola, CEO of Marpai.
Financing Strengthens Marpai's Growth Trajectory
Marpai has experienced significant growth in recent years, driven by its innovative technology platform and commitment to delivering cost-effective, high-quality healthcare solutions to self-funded employers. The Company is well positioned to capitalize on the increasing demand for self-funded health plans, and this new financing will provide Marpai with the resources needed to continue its upward trajectory.
The securities described herein have not been registered under the Securities Act of 1933, as amended, and may not be sold in the United States absent registration or an applicable exemption from the registration requirements.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
ThinkEquity served as advisor to the company on the financing.
About Marpai, Inc.
Marpai, Inc. (Nasdaq: MRAI) is a leading, national TPA company bringing value-oriented health plan services to employers that directly pay for employee health benefits. Primarily competing in the $22 billion TPA sector serving self-funded employer health plans representing over $1 trillion in annual claims. Marpai works to deliver the healthiest member population for the health plan budget. Operating nationwide, Marpai offers access to leading provider networks including Aetna and Cigna and all TPA services. For more information, visit www.marpaihealth.com, the content of which is not incorporated by reference into this press release.
Forward-Looking Statement Disclaimer
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance," "may," "can," "could", "will", "potential", "should," "goal" and variations of these words or similar expressions. For example, the Company is using forward looking statements when it discusses the potential for ongoing growth initiatives, the expected use of proceeds and the belief that this strategic financing demonstrates JGB Management's confidence in its innovative approach to the TPA market and its future potential. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect Marpai's current expectations and speak only as of the date of this release.
Laser Photonics Provides Shareholder Letter and Announces Fourth Quarter and Year-End 2023 Results
Fourth quarter revenue grew by 673%
Fourth quarter operating and net losses improved by 36% and 86%, respectively
https://www.otcmarkets.com/stock/LASE/news/story?e&id=2825562
Monks, I dunno! Something bothers me about this Company. There are things I have read in PRs here that,,,, well kinda weird.. But I wanna do a full DD on this to make sure as it just might be just plain bad IR. Will post back next week. BTW did you happen to see that property in the D.M. that they wanna build on? OMG but is it real?
LOL
Let's see what happens after 4/12. Hope all is well Monks :)
LASER PHOTONICS CORP: Is Hiring
Recruiting Manager | Talent Acquisition | Full-Cycle Recruiter | Onboarding | Proactive Sourcing | Talent Networking | LinkedIn Recruiter | Employee Law & Regulations Hiring a new Industrial Sales Representative -Military Clearance in Orlando, Florida. Apply today or share this post with your network.
Laser Photonics Corporation
Industrial Sales Representative -Military Clearance
Job by Laser Photonics Corporation
Orlando, Florida, United States (On-site)
Jessica Morales
jessimorales01@hotmail.com
Listen, bro. They postponed their 4/1 earnings call. IMHO I don't think its gonna be too good however 2024 numbers should be spectacular! I already sold out for large gain and will buy in again after Earnings. If I am correct then we should see $1.50 again.
Laser Photonics Secures Order From L3Harris Technologies for LaserTower Marking & Engraving System
ORLANDO, Fla.--(BUSINESS WIRE)-- Laser Photonics Corporation (LPC) (NASDAQ: LASE), a leading global developer of industrial laser systems for laser cleaning and other material processing applications, announced that it received an order for its LaserTower COMPACT marking and engraving system from L3Harris Technologies, Inc.
“Laser Photonics is proud to supply laser marking equipment to L3Harris, one of the largest long-time defense contractors in the United States,” said Wayne Tupuola, CEO of Laser Photonics. “This deal underscores our commitment to excellence and innovation. We look forward to delivering cutting-edge solutions that will enhance their operations and contribute to forging a future that is safer and more technologically advanced.”
L3Harris will use LPC’s LaserTower COMPACT system at its semiconductor division in Palm Bay, Florida. The company focuses on command and control systems, precision munitions, avionics and electronic systems, and other specialized equipment for the government, defense and commercial sectors.
The LaserTower COMPACT is an industrial-grade laser marking, engraving and etching system that can operate as a stand-alone unit or get integrated into an I/O production line. Our LaserTower series offers effortless “plug and play” setup, user-friendly operation and enduring performance. It’s the ideal solution for precise, legible, permanent direct part marking, including UDI/UID barcodes, logos and other service marks for a wide range of materials. The system integrates LPC’s proprietary technology for easy barcode scanning.
For more information about the LaserTower line of laser marking and engraving systems, please visit https://www.laserphotonics.com or contact our sales department at fiberlaser@laserphotonics.com.
This 1-month run has been nothing short of outstanding!